Survival Benefit Needed to Undergo Chemotherapy: Patients’ and Physicians’ Preferences: Patient and Physician Preferences instead of Patients’ and Physicians’ Preferences

BACKGROUND: Prior studies suggested that most patients with early stage breast cancer (BC) were willing, for modest survival benefits, to receive 6 months of adjuvant cyclophosphamide, methotrexate, and 5-fluorouracil, an older regimen that is infrequently used today. We examined preferences regardi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer
Hauptverfasser: Vaz-Luis, Ines, O’Neill, Anne, Sepucha, Karen, Miller, Kathy D, Baker, Emily, Dang, Chau T, Northfelt, Donald W, Winer, Eric P, Sledge, George W, Schneider, Bryan, Partridge, Ann H
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2017
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5517352/
https://ncbi.nlm.nih.gov/pubmed/28323331
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.30671
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge